In vivo electrochemical evidence for an enkephalinergic modulation underlying stereotyped behavior: reversibility by naloxone

Exploration of known stereotypic behaviour-related candidate genes in equine crib-biting

Crib-biting in horses is a stereotypic oral behaviour. Genetic susceptibility has been suggested on a causal basis, together with environmental factors such as stress, gastric discomfort and frustration caused by stall restrictions. This study aimed to test the associations of known or suspected stereotypic genes with equine crib-biting, including Ghrelin, Ghrelin receptor, Leptin, Dopamine receptor, μ-opioid receptor, N-cadherin, Serotonin receptor and Semaphorin. We conducted a candidate gene study with a case-control design, including 98 crib-biting and 135 control horses of two breeds, Finnhorses and half-breds. Detailed phenotypic information on crib-biting behaviour was surveyed through an owner-completed questionnaire. Control horses were more than 10 years old and without a history of crib-biting. Single nucleotide polymorphisms flanking the candidate genes were genotyped using either Sanger sequencing or Taqman assays. According to the survey, the affected horses started crib-biting at a young age, had exhibited crib-biting for more than a year, and expressed the behaviour after feeding or when stressed. Comparison of allele frequencies between the cases and controls for each breed separately did not provide evidence of an association at any of the tested loci. These results suggest that the previously known stereotypic genes are not major risk factors for crib-biting in horses, and further genome-wide studies are warranted on larger sample cohorts.

Ultrastructural immunocytochemical localization of mu-opioid receptors in dendritic targets of dopaminergic terminals in the rat caudate-putamen nucleus

Many motor effects of opiates acting at mu-opioid receptors are thought to reflect functional interactions with dopaminergic inputs to the caudate-putamen nucleus. We examined the cellular and subcellular bases for this interaction in the rat caudate-putamen nucleus by dual immunocytochemical labelling for mu-opioid receptors and tyrosine hydroxylase, a marker mainly for dopamine in this region. mu-Opioid receptor-like immunoreactivity showed a patchy distribution by light microscopy. Within the patches, electron microscopy revealed that immunogold labelling for mu-opioid receptors was mainly distributed along extrasynaptic plasma membranes of medium spiny neurons. In contrast, immunoperoxidase labelling for tyrosine hydroxylase was exclusively located in axons and axon terminals without detectable mu-opioid receptor-like immunoreactivity. Forty-six percent of the total mu-opioid receptor-labelled neuronal profiles (n = 1441) were in contact with tyrosine hydroxylase-immunoreactive axons and terminals. These contacts were characterized by closely apposed parallel plasma membrane segments, without well-defined synaptic junctions, or with punctate symmetric specializations. From 639 noted appositions, over 90% were between mu-opioid receptor-labelled dendrites and/or dendritic spines and tyrosine hydroxylase-containing terminals. The dendritic spines containing mu-opioid receptor-like immunoreactivity often received asymmetric synapses characteristics of excitatory inputs from unlabelled terminals. Axon terminals containing mu-opioid receptor-like immunoreactivity formed asymmetric synapses with dendritic spines, or apposed tyrosine hydroxylase-labelled terminals. Our results suggest that, in striatal patch compartments, mu-agonists and dopamine dually modulate the activity of single spiny neurons mainly through changes in their postsynaptic responses to excitatory inputs. In addition, our findings implicate mu-opioid receptors and dopamine in the presynaptic regulation of excitatory neurotransmitter release within the striatal patch compartments.

Effects of naloxone on amphetamine induced striatal dopamine release in vivo: a microdialysis study

The opiate antagonist naloxone (NX) alters amphetamine (AMPH) induced behaviors including locomotor activity, rearing and stereotypy. However, the exact nature of the NX induced alteration of AMPH induced behaviors is controversial, with some studies using high (5-40 mg/kg) doses of NX reporting an inhibition, and others using low (< or = 1-2 mg/kg) doses observing a potentiation. As these behaviors are mediated by AMPH induced dopamine (DA) release, the effect of NX on the latter was examined by microdialysis in an effort to resolve the controversy. Saline and NX pretreated groups subsequently administered AMPH were compared in vivo across nine separate 10 min intervals as well as by grouped intervals. NX alone (0.8 mg/kg) and saline exerted statistically equivalent effects on striatal DA release with the exception of the fifth interval, where a small but significant increase was seen after NX. On the other hand, the same dose of NX significantly enhanced AMPH induced striatal DA release relative to saline pretreated animals during each of four separate intervals, from 30 to 70 minutes following AMPH (1.5 mg/kg), and across all nine intervals combined. NX pretreatment (0.8 mg/kg) followed by a higher dose of AMPH (3.0 mg/kg) produced a significantly greater cumulative effect on DA release than saline pretreatment over the last six combined intervals (30-90 min) and over two grouped intervals (30-50 min and 40-60 min inclusive). However, a comparison of single rather than paired or grouped intervals revealed no significant differences. Previous studies have also examined the effect of NX on AMPH induced striatal DA release using in vivo microdialysis. However, the doses used were invariably high (5 mg/kg) and the results on striatal DA release always inhibitory. The present results suggest that NX potentiates AMPH induced striatal DA release when lower doses of NX are used. These results combined with those of previous studies also suggest that NX exerts a biphasic effect on AMPH induced DA release, with lower doses potentiating release and higher doses inhibiting release. This is close agreement with behavioral observations and may be due to the effect of low versus high doses of NX on intraterminal calcium influx.

Comparison of delta opiate receptor agonist induced reward and motor effects between the ventral pallidum and dorsal striatum

The role of the ventral pallidum and the dorsal striatum in mediating the rewarding effects of the delta receptor specific agonist [2-D-penicillamine, 5-D-penicillamine]enkephalin (DPDPE) were evaluated in the rat using the intracranial self-stimulation paradigm. Reward shifts were indicated by the change in frequency required to maintain half-maximal responding while motor/performance changes were identified by increases or decreases in the maximum responding. Each hour-long test session consisted of three identical, consecutive 20 min rate-frequency curves. In an effort to ascertain possible heterogeneity of function along the rostrocaudal axis, DPDPE (0.0 nmol = saline dose, 0.3 nmol = low dose, 1.0 nmol = medium dose, 3.0 nmol = high dose) was microinjected into either the rostral or caudal region of the two structures. Microinjections into the caudate were positioned directly above the ventral pallidum placements resulting in centromedial or caudomedial caudate placements. DPDPE microinjections into the rostral ventral pallidum resulted in a significant reward increase (28% increase or -0.14 log Hg shift) only at the high dose. In contrast, caudal ventral pallidal DPDPE microinjections showed a dose-response effect with reward increases of 19, 22 and 31% (-0.09, -0.11 and -0.16 log Hz) for the low, medium and high dose, respectively. DPDPE microinjections into the centromedial caudate resulted in a large reward increase (29% or -0.15 log Hz) at the high dose, while caudomedial caudate DPDPE microinjections had no effect on reward. Motor/performance effects tended to follow the pattern of reward effects, with most regions showing motor increases ranging from 25 to 75% over baseline activity. The only exception was found in the caudomedial caudate, where microinjections of the high dose of DPDPE resulted in an approximate 20% suppression of motor/performance activity. These results demonstrate that the ventral pallidum and the mediocentral caudate play a role in modulating opiate rewards, and adds to the growing body of literature regarding the regional heterogeneity within the caudate and ventral pallidum.

Cellular basis for interactions between catecholaminergic afferents and neurons containing leu-enkephalin-like immunoreactivity in rat caudate-putamen nuclei

Dopaminergic afferents to the dorsal striatum, caudate-putamen nuclei, are known to modulate the levels and synthesis of endogenous opiate peptides (Leu5 and Met5-enkephalins). We examined the dual immunocytochemical localization of antisera raised against Leu5-enkephalin and the catecholamine-synthesizing enzyme, tyrosine hydroxylase (TH), to determine the cellular substrates for these and/or other functional interactions. The antisera were identified by combined immunogold-silver and immunoperoxidase labeling in single coronal sections through the caudate-putamen nuclei of adult rats. These animals were given intraventricular injections of colchicine, and the brains were fixed by acrolein perfusion prior to immunocytochemical labeling. By light microscopy, perikarya and processes containing enkephalin-like immunoreactivity (ELI) were seen in close proximity to varicose processes immunoreactive for TH. Electron microscopy further demonstrated that the ELI was localized to perikarya, dendrites, and axon terminals, whereas the TH was exclusively in axons and terminals. The dendrites containing ELI were postsynaptic to terminals that were either (1) without detectable immunoreactivity, or (2) immunoreactive for TH or enkephalin. Nonsynaptic portions of the dendrites containing ELI were covered with astrocytic processes or were in direct apposition to unlabeled dendrites. Terminals containing ELI were densely immunoreactive and were in direct contact with (1) unlabeled and occasionally enkephalin-labeled proximal dendrites, and (2) TH-labeled and unlabeled terminals. In comparison with the opiate terminals, most catecholaminergic terminals were lightly immunoreactive for TH and usually contacted more distal unlabeled dendrites or spines and, more rarely, dendrites containing ELI. In a few favorable planes of section, the terminals containing ELI and those containing TH (1) converged on common unlabeled dendrites, or (2) formed dual contacts on two different labeled or unlabeled targets. Junctions formed by terminals containing ELI and TH were sometimes characterized by symmetric synaptic densities. However, numerous other dendritic and all axonal appositions were without recognized membrane densities. The findings of the study provide anatomical substrates for multilevel interactions between catecholamines, mostly dopamine, and enkephalin in rat dorsal striatum. These include (1) monosynaptic input from dopaminergic terminals to neurons containing enkephalin, (2) presynaptic modulation of transmitter release through axonal appositions, and (3) dual regulation of common targets through convergent input. In addition, the findings suggest that both enkephalin and dopamine may have similar modulatory roles in synchronizing the activity of dual targets postsynaptic to individual axon terminals. Alterations in any one of these multiple types of interactions could account for noted motor or sensory symptoms in neurological disorders characterized by depletion of dopamine or endogenous opiate peptides, or both.

Enkephalin prevents CCK-induced enhancement of amphetamine-induced locomotor stereotypy

Enkephalin (ENK) and/or cholecystokinin octapeptide (CCK-8) were infused into nucleus accumbens of rats prior to injection with saline or 1.0 mg/kg amphetamine. Behavior was observed in an open-field paradigm which allowed assessment of locomotor stereotypy (repetitive routes or patterns of locomotion) as well as assessment of lines crossed and rears. Neither CCK nor ENK nor the combination of the two affected the behavior of saline-injected rats in the open field. CCK enhanced the locomotor stereotypy produced by amphetamine without affecting any of the other behaviors recorded. ENK had no effect on the behavior of amphetamine-treated rats when given alone, but ENK prevented the effect of CCK. Thus, enkephalin and CCK interact to modulate amphetamine-induced locomotor stereotypy.

Stress-induced decrease of 3-methoxytyramine in the nucleus accumbens of the mouse is prevented by naltrexone pretreatment

Pretreatment with naltrexone (2.5 and 5 mg/kg) prevented the decrease of 3-methoxytyramine (3-MT)/dopamine (DA) ratio induced by 2 h immobilization stress in the nucleus accumbens (NAS) of the mouse while it did not affect the stress-induced decrease of 3-MT/DA ratio in caudatus putamen (CP). Naltrexone also produced a slight antagonism of homovanillic acid (HVA)/DA ratio increase produced by stress in the frontal cortex (FC). These results point to an involvement of endogenous opioids in the effects of stress on DA metabolism in the mesolimbic system of the mouse.

A potent dopamine-releasing factor is present in high concentrations in the rat adrenal gland

The present study shows that a novel, protease-sensitive factor present in a partially purified preparation from the rat adrenal gland selectively stimulates the release of dopamine from the rat striatal tissue superfused in vitro in a dose-dependent manner. Biological activity is also found to be present in much lower concentrations in the neocortex, striatum and cerebellum but absent in liver or spleen. This putative dopamine releasing factor is probably a glycoprotein, resistent to boiling, partially inactivated by trypsin and completely inactivated by the non-specific protease pronase E.

The importance of striatal interneurons in age-related effects upon potassium- and amphetamine-stimulated dopamine release

The ability of superfused corpus striatal tissue fragments to release endogenous dopamine (DA) in response to potassium (K+ 30 mM) stimulation was significantly attenuated in 18- to 24-month- compared to 2- to 4-month-old male rats. These age-related effects on K+ stimulation were completely abolished with the addition of tetrodotoxin (1 microM) to the superfusion medium. Moreover, no difference in stimulated DA release was obtained between these two age groups following amphetamine stimulation (10 microM).

Striatal neurochemistry of dynorphin-(1-13): in vivo electrochemical semidifferential analyses

The striatal neurochemistry of dynorphin-(1-13) was studied by simultaneously measuring extracellular dopamine and serotonin voltammetrically and in vivo after the injection of dynorphin-(1-13) to male Sprague-Dawley rats. The subcutaneous administration of dynorphin-(1-13), at a dose (1.5 mg/kg), known to exert CNS mediated behavioral effects, caused a statistically significant decrease in extracellular dopamine and a statistically significant increase in extracellular serotonin from rat anterior striatum. These parallel and opposite effects of dynorphin-(1-13) on these biogenic amines occurred gradually during a three hour time course. Maximal effects on dopamine (55%) and on serotonin (62%) occurred at the end of the three hour period of study. Mean effects on dopamine and serotonin (35% and 42% respectively) were averaged from scan results over the three hour period of study; the results were significantly different from control values. Dose response studies showed that a lower dose of dynorphin-(1-13) (0.5 mg/kg sc) had little or no effect on the alteration of these biogenic amines from striatum. The highest dose of dynorphin-(1-13) studied, (3.0 mg/kg sc), predictably and significantly altered extracellular biogenic amines. The dose response, however, was not incremental. The results are consistent with the role of dynorphin-(1-13) as a neuromodulatory peptide. The results further support the concept that the neuromodulatory role of dynorphin-(1-13) may take place through neurotransmitter regulation. The data suggest that the function of dynorphin-(1-13) may be a presynaptic modulation of neurotransmission in striatum.

Glutamate-evoked release of endogenous brain dopamine: inhibition by an excitatory amino acid antagonist and an enkephalin analogue

The present study examined the effect of a selective delta-opioid receptor agonist [D-Ala2-D-Leu5] enkephalin (DADL) on the spontaneous and the L-glutamic acid (L-Glu)-evoked release of endogenous dopamine from superfused slices of rat caudate-putamen. The amount of dopamine in slice superfusates was measured by a sensitive method employing high-performance liquid chromatography with electrochemical detection (h.p.l.c.-e.d.) after a two-step separation procedure. The spontaneous release of endogenous dopamine was partially dependent on Ca2+, enhanced in Mg2+-free superfusion medium, partially reduced by tetrodotoxin (TTX, 0.3 microM), partially reduced by the putative excitatory amino acid receptor antagonist DL-2-amino-7-phosphonoheptanoic acid (DL-APH, 1 mM), and increased 10 fold by the dopamine uptake blocker, nomifensine (10 microM). DADL (5 and 50 nM) did not significantly affect spontaneous dopamine release. L-Glu (0.1-10 mM) produced a concentration-dependent release of endogenous dopamine from slices of caudate-putamen. This effect was Ca2+-dependent, strongly inhibited by 1.2 mM Mg2+, attenuated by DL-APH (1 mM), attenuated by TTX (0.3 microM), and enhanced by nomifensine (10 microM). In the presence of nomifensine DADL (50 nM) reduced significantly the L-Glu-evoked release of endogenous dopamine by 20%. The inhibitory effect of DADL was blocked by 10 microM naloxone. These results indicate that L-Glu stimulates the Ca2+-dependent release of endogenous dopamine in the caudate-putamen by activation of N-methy-D-aspartate-type of excitatory amino acid receptors. This release can be selectively modified by the delta-opioid agonist DADL in a naloxone-sensitive manner.

A functional separation of behavioral stereotypy based on naloxone-reversible effects of seryl enkephalinamide: comparison with morphine

Amphetamine's stereotypic behavioral actions, produced by the stimulant at a moderate dose, were inhibited by the systemic administration of seryl enkephalinamide, D-Ser2-D-Ser5-enkephalinamide, (Wy 42,896). The classical sequelae of stimulatory behavioral events: sniffing, head bobbing, rearing and locomotor activity, were significantly inhibited by the seryl enkephalinamide. Subsequently, pretreatment with the opiate receptor antagonist, naloxone, significantly blocked the inhibitory effects of the seryl enkephalinamide on the stereotypic and locomotor components. Concomitantly, the behavioral stereotypic component, licking, a behavior usually produced by opiates and only high doses of amphetamine, was significantly induced by the seryl enkephalinamide. Pretreatment with naloxone on the stimulatory behavioral effect of licking, produced a significant inhibitory effect. The combination treatment, consisting of both the seryl enkephalinamide and the stimulant amphetamine, caused a naloxone-reversible synergistic effect. These data show that the seryl enkephalinamide, produced concomitant, naloxone-reversible, inhibitory and stimulatory behavioral stereotypic effects. These data are discussed within the context of current neuronal theories which might underly the observed dose-related continuum of behavioral stereotypies produced by morphine and amphetamine.

Intermittent infusion of progesterone potentiates whereas continuous infusion reduces amphetamine-stimulated dopamine release from ovariectomized estrogen-primed rat striatal fragments superfused in vitro

In the present experiment we examined the effect of a direct in vitro infusion of progesterone upon spontaneous and amphetamine-stimulated in vitro dopamine (DA) release and post-superfusion DA tissue concentration of corpus striatum tissue fragments from ovariectomized and estrogen-treated female rats. An intermittent infusion of progesterone at a dose of 2 ng/ml produced a significant increase in amphetamine-stimulated DA release and post-superfusion DA tissue concentration compared to similar superfusions infused with medium alone or cholesterol (2 ng/ml). Higher (50 ng/ml) or lower (0.2 ng/ml) doses of progesterone were ineffective and a continuous infusion of progesterone at an identical total concentration to that of the intermittent 2 ng/ml dose inhibited both amphetamine-stimulated DA release and post-superfusion DA tissue concentration. With the exception of 5 alpha DHP (dihydroxyprogesterone) intermittent infusions of various metabolites, a synthetic progestin (R5020) at 2 ng/ml and estradiol at both 0.2 ng/ml and 2 ng/ml failed to modify significantly the amphetamine-stimulated DA response. However, pregnanolone, 5 alpha DHP, R5020 at 2 ng/ml and estradiol at 0.2 ng/ml increased post-superfusion DA tissue concentration to levels comparable to that of progesterone. These results demonstrate that in vitro progesterone can directly alter the amphetamine-stimulated DA release from dopaminergic terminals of corpus striatal tissue fragments. This effect appears quite specific for progesterone as well as for a specific dose and mode of infusion of this gonadal steroid. Moreover, progesterone can exert opposite effects upon the amphetamine-evoked DA release from the corpus striatum as a function of its mode of infusion suggesting a means by which one hormone can differentially alter central nervous system function.

Neuropeptide modulation of apomorphine-induced stereotyped behavior

The nucleus accumbens contains many neuropeptides whose functions are presently unknown. The purpose of this study was to determine the extent to which these neuropeptides act in conjunction with the mesolimbic dopamine system. Microinjections of cholecystokinin, neurotensin, met-enkephalin, somatostatin, bombesin, as well as glutamate and muscimol, were made into the medial nucleus accumbens after systemic injection of apomorphine. Cholecystokinin and neurotensin, in nanogram doses, potentiated apomorphine-induced stereotypy. Met-enkephalin reduced, while somatostatin and bombesin were without effect on, apomorphine-induced stereotypy. In addition, both glutamate and muscimol potentiated this effect. These results suggest that several neuropeptides and amino acids act in the nucleus accumbens to modulate apomorphine-induced stereotyped behaviors.

Daily changes in in vitro spontaneous dopamine efflux from the corpus striatum of male rats

In the present experiment we examined the spontaneous in vitro dopamine (DA) efflux from superfused corpus striatum (CS) of male rats at 3-hr intervals throughout a 24-hr photoperiod (lights on 0500-1900 hr). Maximal mean efflux, and post-superfusion DA concentrations were obtained at 0600 hr. With the exception of 0600 hr, mean efflux was lower during the light compared to the dark phase. Interestingly, the direction of the efflux profiles also varied as a function of time demonstrating increasing, decreasing and relatively stable profiles over the superfusion period. These changes in overall mean efflux, post-superfusion tissue concentration and efflux rate profile direction indicate that circadian processes play a complex role upon the synthesis/release process of DA from the nigrostriatal dopaminergic system that is revealed under the dynamic conditions of in vitro superfusion of isolated CS fragments.

Antagonism of footshock stress-induced inhibition of intracranial self-stimulation by naloxone or methamphetamine

Rats were trained to lever-press for intracranial self-stimulation (ICSS) with electrodes implanted in the ventral tegmental area (VTA). The effect of inescapable footshock on response rates to ICSS was examined in the present study. Markedly decreased response rates to ICSS were observed 15 min to 24 h following inescapable footshock. Naloxone (10.0 mg/kg) itself was without effect on response rates to ICSS, but completely antagonized the decreased response rates by the stressor treatment. A relatively low dose of methamphetamine (0.5 mg/kg), which showed no effect on ICSS rates in naive rats, also antagonized the decreased response rates to ICSS. The present results suggest that inescapable footshock may release endorphin in the mesolimbic or mesocortical area; the released endorphin may act on dopaminergic nerve endings and interrupt dopaminergic transmission. The decreased activity of dopaminergic neurons may cause the decreased response rates to ICSS.

In vivo electrochemical studies of rat striatal dopamine and serotonin release after morphine

The effect of the reference opiate, morphine (d-morphine-sulfate), on endogenously released striatal dopamine and serotonin was studied in male, adult, anesthetized Sprague-Dawley rats. The intraperitoneal administration of morphine produced a biphasic effect on striatal dopamine release. A significant increase in the dopamine signal was seen in the first hour after drug administration; a significant decrease in the dopamine signal was seen in the second and third hour after drug administration. On the other hand, the effect of morphine on striatal serotonin release was monophasic. Morphine significantly increased serotonin release from rat striatum. The effect lasted three hours after morphine administration, i.e., the effect persisted significantly throughout the study. These data show a simultaneous opiate-dopaminergic and opiate-serotonergic interaction in rat striatum. These data further extend studies which have suggested that the pharmacological mechanism of action of morphine may have its etiology in the concurrent modulation of more than one neurotransmitter.

Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study

The distribution of methionine-enkephalin (ME)-like and substance P (SP)-like immunoreactivity in the basal ganglia of untreated schizophrenics as compared with normal control cases, and untreated Huntington and Parkinson patients was studied using the unlabeled peroxidase-antiperoxidase (PAP) method. ME but not SP was reduced in the pallidum of one of six schizophrenics. The remaining five cases showed no differences to the controls. In contrast, no or only very faint homogeneously distributed ME and SP was found in any part of the basal ganglia in Huntington's disease. In Parkinson's disease, SP immunoreactivity was within normal range.

Caudate electrochemical response following amphetamine administration in pigtail monkeys

In vivo electrochemical and heart rate (HR) recordings following amphetamine (AMPH) (0.8 mg/kg) and saline administration were made from caudate in four young adult pigtail (M. nemestrina) monkeys using linear sweep voltammetry. One hour following drug injection, two familiar humans served as test stimuli, and were visually exposed to the animals for 15-minute epochs each. One was threatening to the animals, and one was not. AMPH produced a significant increase in height of the electrochemical peak thought to represent oxidation of dopamine and its metabolites. Heart rate (HR) decreased during the time the peak height was increasing. HR and peak height increased during presentation of both humans under both AMPH and saline conditions. However, peak height increase under AMPH, but not saline, conditions discriminated the negative from neutral stimulus. The findings demonstrate that AMPH administration induces a significant increase in the height of a major electroactive peak in the caudate nucleus of pigtail monkeys, and further that such amphetamine-induced increases can be manipulated by altering the affective and/or emotional state of the animal.

Endogenous opiates: 1983

This paper is the sixth in an annual series of reviews of research involving the endogenous opiates, each installment being restricted to work published during the previous year. Although the early articles in the series attempted to be comprehensive and cover the complete range of research with the opiate peptides, in the last two years we have limited our coverage to non-analgesic and behavioral work due to the enormous number of articles published in the field. The specific areas discussed here include stress, tolerance and dependence, consummatory responses, other gastrointestinal functions, interactions with alcohol, mental illness, learning and memory, cardiovascular responses, respiratory effects, thermoregulation, neurological disorders, activity, and miscellaneous other topics. As in previous years, we have attempted to present a relatively complete review of the subjects covered only for the previous year and generally have not tried to evaluate their contributions relative to those of past years.

Chronic stress enhances apomorphine-induced stereotyped behavior in mice: involvement of endogenous opioids

Mice subjected to repeated stressful experiences showed an increase in stereotypic climbing behavior induced by apomorphine thus suggesting a modified sensitivity of dopaminergic receptors. Naltrexone, injected before each stressful experience, reversed this effect of chronic stress indicating an involvement of endogenous opioids.